Your browser doesn't support javascript.
loading
Biocatalysis in Drug Design: Engineered Reductive Aminases (RedAms) Are Used to Access Chiral Building Blocks with Multiple Stereocenters.
Casamajo, Arnau Rué; Yu, Yuqi; Schnepel, Christian; Morrill, Charlotte; Barker, Rhys; Levy, Colin W; Finnigan, James; Spelling, Victor; Westerlund, Kristina; Petchey, Mark; Sheppard, Robert J; Lewis, Richard J; Falcioni, Francesco; Hayes, Martin A; Turner, Nicholas J.
Affiliation
  • Casamajo AR; Department of Chemistry, University of Manchester, Manchester Institute of Biotechnology, 131 Princess Street, Manchester M1 7DN, United Kingdom.
  • Yu Y; Department of Chemistry, University of Manchester, Manchester Institute of Biotechnology, 131 Princess Street, Manchester M1 7DN, United Kingdom.
  • Schnepel C; School of Engineering Sciences in Chemistry, Biotechnology and Health, Department of Industrial Biotechnology, KTH Royal Institute of Technology, AlbaNova University Center, 11421 Stockholm, Sweden.
  • Morrill C; Department of Chemistry, University of Manchester, Manchester Institute of Biotechnology, 131 Princess Street, Manchester M1 7DN, United Kingdom.
  • Barker R; Department of Chemistry, University of Manchester, Manchester Institute of Biotechnology, 131 Princess Street, Manchester M1 7DN, United Kingdom.
  • Levy CW; Department of Chemistry, University of Manchester, Manchester Institute of Biotechnology, 131 Princess Street, Manchester M1 7DN, United Kingdom.
  • Finnigan J; Prozomix Ltd, Building 4, West End Ind. Estate, Haltwhistle NE49 9HA, United Kingdom.
  • Spelling V; Early Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca, Mölndal, 431 50 Gothenburg, Sweden.
  • Westerlund K; Medicinal Chemistry, Research and Early Development; Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal, 431 50 Gothenburg Sweden.
  • Petchey M; Compound Synthesis and Management, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Mölndal, 431 50 Gothenburg, Sweden.
  • Sheppard RJ; Medicinal Chemistry, Research and Early Development; Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal, 431 50 Gothenburg Sweden.
  • Lewis RJ; Department of Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, 43183 Mölndal, Sweden.
  • Falcioni F; Early Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca, CB21 6GP Cambridge, United Kingdom.
  • Hayes MA; Compound Synthesis and Management, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Mölndal, 431 50 Gothenburg, Sweden.
  • Turner NJ; Department of Chemistry, University of Manchester, Manchester Institute of Biotechnology, 131 Princess Street, Manchester M1 7DN, United Kingdom.
J Am Chem Soc ; 145(40): 22041-22046, 2023 10 11.
Article in En | MEDLINE | ID: mdl-37782882
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Design / Amines Language: En Journal: J Am Chem Soc Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Design / Amines Language: En Journal: J Am Chem Soc Year: 2023 Document type: Article Affiliation country: Country of publication: